Dr Reddy's Gains Nearly 1% On Launching Albendazole Tablets In U.S.

Albendazole tablets are a therapeutic equivalent generic version of Albenza tablets, 200 mg, approved by the U.S. Food and Drug Administration

Dr Reddy's Laboratories shares gained nearly one per cent on the BSE after the company announced the launch of albendazole tablets in the US market. At 10:40 am, the shares of Dr. Reddy's Laboratories were trading at Rs 5,143, higher by 0.82 per cent on the BSE. Albendazole tablets are a therapeutic equivalent generic version of Albenza tablets, 200 mg, approved by the U.S. Food and Drug Administration. The Albenza brand and generic had U.S. sales of about $27 million MAT for the twelve months ended November 2020.